ArticleClinical kidney journal2025
Urinary endotrophin as a biomarker for T cell-mediated rejection-associated fibrogenesis in kidney transplant recipients.
Article in Clinical kidney journal, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
- Erratum issued
Authors and funding
14 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Endotrophin, a C-terminal pro-collagen type VIα3 fragment, has been shown to correlate with kidney interstitial fibrosis, kidney outcome measures and survival in various kidney diseases and kidney transplantation. In this study we investigated whether endotrophin is associated with fibrogenesis in T cell-mediated rejection (TCMR), allowing its use as a non-invasive biomarker. Method: Plasma endotrophin and urinary endotrophin (indexed for creatinine) were measured in samples from a cross-sectional study among kidney transplant recipients (KTRs) who underwent indication biopsy after transplantation and enrolled in TransplantLines Biobank and Cohort Study. Endotrophin was measured using the nordicPRO-C6 enzyme-linked immunosorbent assay. Blood and urine were collected on the day of biopsy. In a subset of patients, the biopsy was stained for endotrophin and T cells. Results: A total of 149 KTRs were included in the analyses. Of them, 48 (32.2%) had TCMR (either borderline, acute, chronic or mixed). Higher urinary endotrophin levels were associated with increased odds of TCMR and the association remained significant after adjustment for other potential confounders, including plasma endotrophin [adjusted odds ratio per doubling 1.38 (95% confidence interval 1.11-1.72), Conclusion: These data indicate the potential use of urinary endotrophin as a non-invasive biomarker for fibrogenesis in the context of TCMR.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.